Page 21
( atezolizumab ) and Opdivo ( nivolumab ). The FDA also approved Myriad Genetics ' BRACAnalysis CDx as a complementary diagnostic to help identify ovarian cancer patients most likely to benefit from GSK ’ s / Tesaro ’ s recently approved PARP inhibitor Zejula ( niraparib ).
Figure 16 : CDx from tamoxifen to Tecentriq
Figure 17 : Map kinase pathway drives cancer growth and survival
Source : www . mycancergenome . com
Source : ( Jørgensen & Hersom , Companion diagnostics-a tool to improve pharmacotherapy , 2016 )
Radiopharmaceuticals use a CDx version of the technology to increase success of the paired treatment
Radiopharmaceuticals a novel CDx Companies in the radiopharmaceutical market are releasing diagnostic agents for their therapeutic targeted radionuclides . For example , selection with PSMA / PET imaging is a prerequisite for the treatment of patients that have failed or ceased to respond to androgen receptor pathway inhibition and taxane-based chemotherapy for treatment with Novartis ’ s 177 Lu PSMA targeted prostate cancer radiopharmaceutical Pluvicto . Novartis launched Locametz in May 2022 to ensure the availability of a PSMA / PET diagnostic for this purpose . Other companies follow this path of developing a diagnostic followed by a therapeutic agent to ensure greater chance of success for patients and high-level imaging of lesions .
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .